Brain-derived neurotrophic factor (BDNF) is a key protein in the neurotrophin family, essential for neuronal survival, differentiation, and synaptic plasticity. It plays critical roles in learning, memory, and cognitive function by regulating neurotransmitter release and long-term potentiation. BDNF signals through the TrkB receptor and its precursor, proBDNF, binds to p75NTR, influencing opposing cellular processes. Dysregulation of BDNF is linked to neurological disorders (e.g., Alzheimer’s, Parkinson’s), psychiatric conditions (e.g., depression, anxiety), and metabolic diseases.
BDNF antibodies are vital tools for detecting and quantifying BDNF expression in research and diagnostics. They enable visualization of BDNF distribution in tissues (via immunohistochemistry), quantification in biological fluids (ELISA), and analysis of molecular interactions (Western blot, immunoprecipitation). Specific antibodies distinguish between proBDNF and mature BDNF isoforms, aiding studies on their distinct biological roles. Commercial BDNF antibodies vary in host species, clonality (monoclonal/polyclonal), and epitope targets, requiring validation for specificity to avoid cross-reactivity with related neurotrophins (e.g., NGF, NT-3). Recent advances focus on developing phosphorylation-specific antibodies to study BDNF/TrkB signaling dynamics. Challenges include BDNF's low abundance in biofluids and its susceptibility to proteolytic degradation. Reliable BDNF antibodies remain crucial for exploring its therapeutic potential and biomarker utility in neurological and psychiatric diseases.